Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8+ T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway

Journal of Experimental Medicine

Volumn 194, Issue 8, 2001, Pages 1053-1068

  Lautscham, G ^a   Mayrhofer, S ^a   Taylor, G ^a   Haigh, T ^a   Leese, A ^a   Rickinson, A ^a   Blake, N ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

CD8+epitopes; Epstein Barr virus; Hydrophobicity; MHC class I presentation; TAP independence

Indexed keywords

CARRIER PROTEIN; CELL NUCLEUS ANTIGEN; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; HLA ANTIGEN CLASS 1; LATENT MEMBRANE PROTEIN 2; PROTEASOME; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENDOPLASMIC RETICULUM; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HYDROPHOBICITY; PHENOTYPE; PRIORITY JOURNAL; VACCINIA;

ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TRANSFORMED; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; EPITHELIAL CELLS; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HERPESVIRUS 4, HUMAN; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-B27 ANTIGEN; HUMANS; MULTIENZYME COMPLEXES; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VIRAL MATRIX PROTEINS;

EID: 0035886881     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.194.8.1053     Document Type: Article

References (63)

1. Mechanisms of MHC class I-restricted antigen processing
2. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
3. Evidence that transporters associated with antigen processing translocate a major histocompatibility complex class I-binding peptide into the endoplasmic reticulum in an ATP-dependent manner
4. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter
5. TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective
6. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells
7. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation
8. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction
9. Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules
10. Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope
11. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
12. Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: Dependence on TAP1/2 and mechanisms for cytosolic localization
13. The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol
14. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid
15. HLAA2.1-associated peptides from a mutant cell line: A second pathway of antigen presentation
16. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides
17. + T cells
18. Two novel routes of transporter associated with antigen processing (TAP)-independent major histocompatibility complex class I antigen processing
19. Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum
20. Major histocompatibility complex class I viral antigen processing in the secretory pathway defined by the transGolgi network protease furin
21. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2
22. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: Implications for cytotoxic T-lymphocyte control of EBV-associated malignancies
23. Human peptide transporter deficiency: Importance of HLA-B in the presentation of TAP-independent EBV antigens
24. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases
25. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
26. Major histocompatibility complex class I molecules interact with both subunits of the transporter associated with antigen processing, TAP1 and TAP2
27. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide
28. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing
29. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies
30. Conserved CTL epitopes within EBV latent membrane protein 2: A potential target for CTL-based tumor therapy
31. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
32. A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening
33. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
34. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
35. Vaccinia virus expression vector: Coexpression of β-galactosidase provides visual screening of recombinant virus plaques
36. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response
37. Selection of recombinant vaccinia viruses on the basis of plaque formation
38. Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction
39. A sequential model for peptide binding and transport by the transporters associated with antigen processing
40. Epstein-Barr virus SM protein
41. Polymorphism in the α1 helix of the HLA-B heavy chain can have an overriding influence on peptide-binding specificity
42. Correlation of sequence hydrophobicities measures similarity in three-dimensional protein structure
43. Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing
44. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing
45. Degradation of subunits of the Sec61p complex, an integral component of the ER membrane, by the ubiquitin-proteasome pathway
46. Lactacystin and clasto-lactacystin β-lactone modify multiple proteasome β-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation
47. Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1 ENV epitope for endogenous MHC class I antigen presentation
48. Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme
49. A giant protease with potential to substitute for some functions of the proteasome
50. A proteolytic system that compensates for loss of proteasome function
51. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells
52. Subpopulations of proteasomes in rat liver nuclei, microsomes and cytosol
53. 20S human proteasomes bind with a specific orientation to lipid monolayers in vitro
54. Intracellular targeting of the proteasome
55. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
56. The major substrates for TAP in vivo are derived from newly synthesized proteins
57. The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases
58. Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases
59. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells
60. + T cells in vivo
61. MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies
62. Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel
63. Evidence for peptide transport across microsomal membranes